Literature DB >> 29438968

CD38 pretargeted RIT of B-cell tumors.

Donald J Buchsbaum1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29438968      PMCID： PMC5805492          DOI： 10.1182/blood-2017-12-819011

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Authors:  Donald J Buchsbaum; M B Khazaeli; Donald B Axworthy; Jody Schultz; Tandra R Chaudhuri; Kurt R Zinn; Mark Carpenter; Albert F LoBuglio
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

2.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

3.  Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.

Authors:  Robert M Sharkey; Habibe Karacay; Thomas M Cardillo; Chien-Hsing Chang; William J McBride; Edmund A Rossi; Ivan D Horak; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

4.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

5.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

6.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

Authors:  Steven I Park; Jaideep Shenoi; John M Pagel; Don K Hamlin; D Scott Wilbur; Nural Orgun; Aimee L Kenoyer; Shani Frayo; Amanda Axtman; Tom Bäck; Yukang Lin; Darrell R Fisher; Ajay K Gopal; Damian J Green; Oliver W Press
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

7.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Authors:  Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

8.  CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Authors:  Damian J Green; Shyril O'Steen; Yukang Lin; Melissa L Comstock; Aimee L Kenoyer; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Margaret Nartea; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Kelly D Orcutt; K Dane Wittrup; Oliver W Press
Journal:  Blood       Date:  2017-11-20       Impact factor: 22.113
  8 in total
  2 in total

Review 1.  Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Authors:  Tomas Etrych; Alena Braunova; David Zogala; Lukas Lambert; Nicol Renesova; Pavel Klener
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 2.  Combination Radioimmunotherapy Strategies for Solid Tumors.

Authors:  Javeria Zaheer; Hyeongi Kim; Yong-Jin Lee; Jin Su Kim; Sang Moo Lim
Journal:  Int J Mol Sci       Date:  2019-11-08       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.